B ALL, CD22+ Expression, Refractory B-ALL
Conditions
Keywords
efficacy of Chemo-immunotherapy
Brief summary
Patients with relapsed/refractory adult acute lymphoblastic leukemia (ALL)have a very dismal prognosis. In this case, allogeneic transplantation is the only curative treatment when patient have obtained a second complete remission (CR. In France, in patients younger than 60 years old,the HyperCVAD regimen used by the MDAnderson in Houston is generally applied. In older patients (\>=60 years)or young patients \<= 60 years no eligible for intense chemotherapy, a combination of vincristine + Dexamethasone is generally chosen in order to avoid too much toxicity but the result is worse in term of CR. More than 90% of ALL with a B phenotype (2/3 of cases in adults)express the surface antigen CD22 on leukemic blasts which thus represents an interesting target for therapy. Epratuzumab is a humanized anti-CD22 antibody produced by Immunomedics, Inc, Morris Plain (New Jersey, USA). Epratuzumab has already shown efficacy in lymphoma patients. Only one study, including 15 children, has been published so far reporting the efficacy and the toxicity of Epratuzumab in the setting of ALL in monotherapy, one can observe 8 stable disease, 3 progressions and 4 partial responses. When combining chemotherapy and Epratuzumab, 9CR were observed with acceptable toxicity. Tolerance was acceptable. The French GRAALL group proposes to test an age-adapted combination of chemotherapy + Epratuzumab, in refractory/relapses CD22+ B ALL patients in order to improve their prognosis, in term of CR, survival and of number of patients eligible for allograft.
Interventions
DRUGEpratuzumab
Combination of chemotherapy + Epratuzumab
Sponsors
Nantes University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years * B-ALL (OMs) with \>= 20 % of blasts in bone marrow * CD22+ expression \>= 30% of the blast population * Refractory B-ALL defined by treatment failure after 2 successive courses of induction therapy or relapse \< 6 months after first CR * First relapse of B-ALL * Second relapse or beyond * Performance status 0-2 * Creatinine clearance \>= 50 ml/min (Cockroft formula) * Serum bilirubine \<= 30 µmom/l * Written informed consent
Exclusion criteria
* T-ALL * Meningeal involvement * CD22 expression on tumor cells or \< 30% * HIV positive * Active Hepatitis B or C * Left ventricular ejection fraction \< 50% in patients \<60 years * Contra-indication to Epratuzumab * Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Participation at the same time in another study in which investigational drugs are used * Absence of written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate (CR and CRp) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate (ORR)(CR, CRp and PR) | — |
| Overall survival | — |
| Disease free survival | — |
| CD22 expression after Epratuzumab | — |
| Safety and tolerance of Epratuzumab in combination with chemotherapy | — |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORPatrice CHEVALLIER, MD
Nantes University Hospital
Outcome results
None listed